Immix Biopharma, Inc.
IMMXNASDAQHealthcareBiotechnology
Previous close
$13.66
+$0.50 · +3.80%
IMMX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
37
Expensive
Momentum
79
Gaining
Sentiment
71
Bullish
Risk resilience
61
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteImmix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Ilya Rachman
- Listed since
- Dec 16, 2021
- Employees
- 21
Market position
Day range
Current $13.66
52-week range
Current $13.66
- Open
- $13.44
- Previous close
- $13.16
- Volume
- 1.51M
- 0.96× average
- Average volume
- 1.57M
- Average daily volume
- Market cap
- 743.13M USD
- Beta
- 0.11
- Market reference 1
- 50-day average
- $10.0344
- +36.13% above average
- 200-day average
- $7.9825
- +71.12% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 79.56M USD
- P/E (TTM)
- -15.52×
- P/B (TTM)
- 3.81×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.69×
- Earnings yield
- -17.07%
- Free cash flow yield
- -14.30%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -31.39%
- Return on assets
- -28.08%
- Return on invested capital
- -31.58%
Financial health
- Debt / equity
- 0×
- Current ratio
- 10.01×
- Altman Z-score
- 43.57
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 16.26M USD | 11.29M USD | 8.74M USD | 4.2M USD | 126.53K USD |
| Selling, general, and administrative | 13.7M USD | 11.38M USD | 7.41M USD | 4.02M USD | 1.23M USD |
| Operating expenses | 29.96M USD | 22.67M USD | 16.14M USD | 8.22M USD | 1.35M USD |
| Interest income | 555.53K USD | 1.02M USD | 572.01K USD | — | — |
| Interest expense | — | — | — | 497 USD | 179.85K USD |
| Depreciation and amortization | 364.5K USD | 115.39K USD | 5.47K USD | 2.14K USD | 2.47K USD |
| Operating income | −29.96M USD | −22.67M USD | −16.14M USD | −8.22M USD | −1.35M USD |
| Net income | −29.44M USD | −21.61M USD | −15.43M USD | −8.23M USD | −24.38M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -0.17%
- 11 comparable reports
- Latest EPS result
- -0.18
- Estimate -0.17 · Miss by 5.88%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$22.00
61.05% upsidePrice history unavailable
High $25.00Average $22.00Low $19.00Rating distribution
5 ratingsRecent analyst actions
IMMX news
IMMX peers
ETFs holding IMMX
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI29.07M0.26%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI14.81M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM13.84M0.02%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF5.68M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO5.07M0.03%15.16B USD0.24%$387.37+1.24%
Vanguard Russell 2000 ETFVTWO1.92M0.01%17.4B USD0.06%$121.25+0.74%
iShares Micro-Cap ETFIWC1.86M0.12%1.53B USD0.60%$198.39+1.10%
Direxion Daily S&P Biotech Bull 3X SharesLABU1.15M0.18%645.76M USD0.96%$317.2+4.03%State Street SPDR S&P Biotech ETFXBI- Market value
- 29.07M
- Weight
- 0.26%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 14.81M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 13.84M
- Weight
- 0.02%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 5.68M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 5.07M
- Weight
- 0.03%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.92M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Micro-Cap ETFIWC- Market value
- 1.86M
- Weight
- 0.12%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Direxion Daily S&P Biotech Bull 3X SharesLABU- Market value
- 1.15M
- Weight
- 0.18%
- AUM
- 645.76M USD
- Expense ratio
- 0.96%
- Price / 1D
- $317.2+4.03%
Continue in GoAI
Research IMMXresearch.disclaimer